Importantly, despite expressing very high levels of MGMT (see Supplementary Figure S7) and being resistant to Temozolomide, we show that MTH1 inhibitors efficiently target GBM cultures #7 and #18. This evidence concerns the gene NUDT1 and glioblastoma.